Tax Season is Here! Save 15% on H&R Block Online
iconAll times are GMT -4. The time now is 05:53 PM. | Search:

» StockRants Stock Forum » Public Stock Forums » US Penny Stock Picks » Watch: NPHC Nutra Pharma Corp * New Product *



Reply
 
Thread Tools Search this Thread
Old 05-23-2010, 05:55 PM   Nav to Top  #1
blanchedsoldier
Junior Trader
 
blanchedsoldier's Avatar
 
Join Date: Sep 2009
Location: Ireland
Posts: 24
Favorites: drys,bcs,pxwl
Rep Power: 121
Reputation: 35
blanchedsoldier is on a distinguished road
Default NPHC Nutra Pharma Corp * New Product *

Nutra Pharma Corp. is a development-stage biopharmaceutical company engaged in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. The Company’s wholly owned subsidiary, ReceptoPharm, Inc. (Recepto Pharm) is a development stage biopharmaceutical company, which is engaged in developing technologies to treat the neurological diseases: multiple sclerosis; adrenomyeloneuropathy; amyotrophic lateral sclerosis; myasthenia gravis; and to treat the viral diseases, human immunodeficiency virus (HIV) and hepatitis-C. The Company’s other wholly owned subsidiary Designer Diagnostics, Inc. (Designer Diagnostics) is engaged in marketing diagnostic test kits that are used for the rapid identification of infectious human diseases, such as Tuberculosis (TB) and Mycobacterium avium-intracellulare (MAI).

Nutra Pharma Corp. (OTC: NPHC) last closed on $0.31 with total volume of 225,579 shares as on May 21st, 2010. The company’s average volume stands around 475,000 shares per day. The company’s total outstanding shares amount to 272.92 million out of which 202.41 million shares are floated in the market. Almost 30.70 percent of total outstanding common stock is held by insiders.







NPHC has just released it's 10 Q. It has reported 48% increase in revenue over the last quarter which was a spectacular quarter for NPHC. The 10 Q has re hashed its concerns from the previous 10 k and has additonal costs due to sourcing additional employee increasing its workforce by 50% in and moving to a larger office building in first quarter and scaling up its operations for cobroxin and the launch of its new product Nyloxin.


The company’s management anticipates even better results for the present and coming quarters. At the Nasdaq conference in New York around May 2010 Nutra pharma has promised to focus on shareholder value and promised no dilution to stock will occour. They have put considerable expense into qualifying to move to higher exchange and are satisifed they are a suitably reporting company to that end.


The CEO has openly stated at the Nasdaq conference that sales have been so successful that earlier predictions have been scaled to 8 times higher than anticipated, This quarter is expected to increase 540%. While earnings are slowly moving into postive territory the company will be racing ahead in revenues. Also NPHC is not chasing profits and is a serious bio tech with a healthy pipeline which has so far produced some stunning results. It is carefully building shareholder value and protecting itself in the market.

Cobroxin was formed using a patented technology that is revolutionising the pain relief market. While the foundation of using venom for pain relief has been around since world war 2 and used by in asia Nutra Pharma have invented and patented a technique that has produced an award winning product.

It is more powerful than Morphine and yet has no side effects and is safe to use and non addicitive. Nutra Pharma are now releasing an even more powerful product Nyloxin aimed at the sever stage 3 chronic pain market. While cobroxin is a runaway success, Nyloxin promises to make Nutra Pharma a serious pain medication by prescription across the world.


Why buy NPHC: When the chart forms a solid bottom in the coming days it will be a very hot stock to buy. It has an extremely promising future that guarantees growth you usual;ly only see in emerging economy ADR's. Also you can visibly see sales by XCHO it's distrbutor and your guaranteed a price safety net set above XCHO's share price. These stocks work in unison to form a very safe share price. As far as bio tech's go it's priced fairly cheap.

NPHC gaps up quickly so don't second guess the bottom. Maybe at this price the P.E is around 20. I also see fast growing ones with an average of P.E of 28 so that at this level leaves some potential upside for the share price.

What the markets wants is something that has unstoppable growth. NPHC is that dream stock, and it isn't an unknown chinese company but compnay based in the USA Florida with DR reid one of the leading world experts in the field of this type of pain medicine.

Technically it is gearing up for another mammoth run. It reached a high of .90 last year and since then revenue has increased 4000% and yes that's not a typo 4000 % . NPHC has a new product being launched and with cobroxin being a massive success wth revenues forecast to triple and quadruple we haven't the last of NPHC.

Last edited by blanchedsoldier; 05-23-2010 at 06:06 PM..
blanchedsoldier is offline   Rate this post Yes | No Reply With Quote
Old 05-24-2010, 09:53 AM   Nav to Top  #2
blanchedsoldier
Junior Trader
 
blanchedsoldier's Avatar
 
Join Date: Sep 2009
Location: Ireland
Posts: 24
Favorites: drys,bcs,pxwl
Rep Power: 121
Reputation: 35
blanchedsoldier is on a distinguished road
Thread Starter
Default NPHC, the next biopharmaceutical to EXPLODE!

StocksAlarm.com Dear Traders, Nutra Pharma Corp (OTC:NPHC), is a biopharmaceutical company that deals with acquisitions, licenses, and marketing of pharmaceutical products used in treatments of neurological disorders. During the first quarter of 2010, they generated revenues of $864,424 from their sales of Cobroxin, which is one of the products high on their list in terms of marketing for this coming year. Cobroxin is an over-the-counter pain reliever that is the first to treat moderate to severe pain. During 2010, they are also focusing on another product called Nyloxin OTC and Rx, stronger versions of Cobroxin. By releasing these easily attainable products, they are hoping to bring convenience to consumers and to create awareness about their company.

During the first quarter of 2010, they reported impressive earnings and management is hoping for better results during the coming quarters. Currently, this company is trading at a share price of $0.31, with total volume of 225,579. With the marketing of products like Cobroxin, they are hoping to increase both in share price as well as in volume. By advertising medicines that are producing results and that are easily attained, they are building a more esteemed company image. They hope to attend various conferences in order to increase brand awareness, as well as to seek out international distribution partners for Nyloxin. Their strive for success is adamant considering that they raised a total of $3,060,275 through private placements of shares of their common stock. The sales of Cobroxin, however, only began reflecting their earnings during the fourth quarter of 2009.

In all, their net loss decreased by 6.3% and their interest expense decreased by 19.2% during the first quarter of 2010. This company is demonstrating their current potential for growth, and how they are releasing products that will establish a name for themselves. Their 52-week range is roughly 0.02-0.99, which shows that they have increased a high percentage in terms of their overall share price. With the success of Cobroxin and Nyloxin imminently awaiting, Nutra Pharma Corp. is looking to a more successful 2010 and a continuation of their current results.
blanchedsoldier is offline   Rate this post Yes | No Reply With Quote
Old 05-25-2010, 10:51 AM   Nav to Top  #3
blanchedsoldier
Junior Trader
 
blanchedsoldier's Avatar
 
Join Date: Sep 2009
Location: Ireland
Posts: 24
Favorites: drys,bcs,pxwl
Rep Power: 121
Reputation: 35
blanchedsoldier is on a distinguished road
Thread Starter
Money Nutra Pharma Announces First Manufacturing Release of Nyloxin Rx

Thanks again for the spam EZI.



NPHC has just released a new DRUG, Has rapildy increasing revenues set to double each quarter and is guaranteed no dilution to stock at a conference at NASDAQ. It is consolidating and share price is at an all time low. It trumps XCHO and I think NPHC will market Nyloxin itself. The time to BUY could be today tomorrow or next week, but don't miss out.

I am puttting just one bear to start with and then After the market recovers or when this finishes consolidating.

Newsroom

Nutra Pharma Announces First Manufacturing Release of Nyloxin Rx, a Prescription Treatment for Chronic Pain

May 25, 2010



Nutra Pharma has announced that it has completed the first production run of its prescription pain drug, Nyloxin Rx, and has successfully released it for initial marketing-related distribution.

Nutra Pharma Corp., a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it has completed manufacturing the first batch of its prescription pain reliever, Nyloxin Rx, and has successfully released it for initial marketing-related distribution within the United States.

“We are pleased to be announcing the rollout of the Company’s first prescription drug, Nyloxin Rx,” commented Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. “As we move forward with the launch of Nyloxin Rx, we continue to seek partnerships with established U.S. and international distributors to assist us with ongoing marketing to physician offices, hospitals and medical clinics,” he added.

Nyloxin Rx is a prescription pain reliever clinically proven to treat Stage 3 (severe) chronic pain. Unlike Stage 2 pain, which interferes with both work and sleep, Nyloxin Rx is aimed at treating the most severe pain that inhibits one’s ability to fully function.

The drug, which was developed by Nutra Pharma’s wholly-owned drug discovery subsidiary, ReceptoPharm, will be available as an oral spray for treating angina pectoris, angina faucium, back pain, headaches, joint pain, migraines, neck pain, neuralgia, ovarian pain, and painful periods and as a topical gel for treating joint pain and pain associated with repetitive stress and arthritis.

Currently, physicians can request samples of Nyloxin Rx by visiting the Healthcare Providers section of the Nyloxin website: Nyloxin // Chronic Pain Relief // Healthcare Providers.


SEC Disclaimer


This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. Announcing the first manufacturing release of Nyloxin Rx should not be construed as an indication in any way whatsoever of the future value of the Company’s common stock or its financial value. The Company's filings may be accessed at the SEC's Edgar system at U.S. Securities and Exchange Commission (Home Page). Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.





Contact

David Isserman
Investor Relations
Toll-Free: (877) 895-5647
investor.relations@nutrapharma.com
blanchedsoldier is offline   Rate this post Yes | No Reply With Quote
Old 05-27-2010, 07:24 PM   Nav to Top  #4
blanchedsoldier
Junior Trader
 
blanchedsoldier's Avatar
 
Join Date: Sep 2009
Location: Ireland
Posts: 24
Favorites: drys,bcs,pxwl
Rep Power: 121
Reputation: 35
blanchedsoldier is on a distinguished road
Thread Starter
Default NPHC possibly about to reverse trend

NPHC has indicated a higher low yesterday with a higher ratio of buys suggesting it is on the cusp of a reversal.


Today NPHC indicated the exact same low as yesterday.

blanchedsoldier is offline   Rate this post Yes | No Reply With Quote
Old 06-01-2010, 01:01 PM   Nav to Top  #5
blanchedsoldier
Junior Trader
 
blanchedsoldier's Avatar
 
Join Date: Sep 2009
Location: Ireland
Posts: 24
Favorites: drys,bcs,pxwl
Rep Power: 121
Reputation: 35
blanchedsoldier is on a distinguished road
Thread Starter
Default ALL bulls this time and no more Bears ( hopefully)

[

Nutra Pharma Partners With Henry Schein for Distribution of Nyloxin-Branded Pain Relievers

CORAL SPRINGS, FL -- (Marketwire)
06/01/10
Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it has partnered with leading healthcare products distributor, Henry Schein, for distribution of its Nyloxin-branded pain relievers in the United States.

Henry Schein, which ranks #339 on the Fortune 500 list, is the largest distributor of healthcare products and services to medical, dental, and veterinary office-based practitioners. With more than 12,500 "Team Schein Members" worldwide, the Company currently serves approximately 45% of the estimated 250,000 U.S. office-based physician practices, surgical centers and other alternate-care sites. Additionally, the Company serves approximately 85% of the estimated 136,000 U.S. and Canadian office-based dental practices, dental laboratories, as well as governments and other institutions and approximately 75% of the estimated 27,000 U.S. animal health practices.

"As one of the furthest reaching and most admired distributors of healthcare products, we are pleased to partner with Henry Schein for distribution of Nyloxin in the United States," commented Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. "We look forward to strengthening our Nyloxin-brand by working closely with Henry Schein to support their distribution of Nyloxin," he said.

Nutra Pharma currently offers two pain relievers under the Nyloxin brand, Nyloxin OTC and Nyloxin Rx. Nyloxin OTC is the Company's over-the-counter (OTC) treatment for moderate to severe (Stage 2) chronic pain. Nyloxin Rx is the Company's prescription treatment for severe (Stage 3) chronic pain. Unlike Stage 2 pain, which interferes with both work and sleep, Nyloxin Rx is aimed at treating the most severe pain that inhibits one's ability to fully function. Both Nyloxin OTC and Nyloxin Rx are manufactured by Nutra Pharma's wholly-owned drug discovery subsidiary, ReceptoPharm, and are available as an oral spray and topical gel.

In addition, Nutra Pharma recently announced the first manufacturing release of Nyloxin Rx for marketing-related distribution. Physicians can currently request samples of Nyloxin Rx through the Healthcare Providers' section of the Nyloxin website: Nyloxin // Chronic Pain Relief // Healthcare Providers.

About Nutra Pharma Corp.

Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases.

The company, through its subsidiaries, carries out basic drug discovery research and clinical development, and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process.

Currently, Nutra Pharma offers several drug products for sale for the treatment of pain: Cobroxin, the first over-the-counter (OTC) pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain, and Nyloxin Rx, the only non-narcotic and non-addictive treatment for severe (Stage 3) pain. Both Cobroxin and Nyloxin were developed by Nutra Pharma's wholly-owned drug discovery subsidiary, ReceptoPharm.

In addition to manufacturing Cobroxin and Nyloxin, ReceptoPharm is also developing proprietary therapeutic protein products primarily for the prevention and treatment of viral and neurological diseases, including Multiple Sclerosis (MS), Adrenomyeloneuropathy (AMN), and Human Immunodeficiency Virus (HIV), and pain in humans. Outside of its role as the drug discovery arm for Nutra Pharma, ReceptoPharm provides contract research services through its ISO class 5 and GMP certified facilities.

The company's wholly-owned medical devices subsidiary, Designer Diagnostics, engages in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases, such as Nontuberculous Mycobacteria (NTM).

Nutra Pharma continues to identify intellectual property and companies in the biotechnology arena as potential acquisition candidates.

Nutra Pharma Corp. (NPC) :: Drug Discovery and Medical Devices

Nyloxin // Chronic Pain Relief
blanchedsoldier is offline   Rate this post Yes | No Reply With Quote
Old 06-01-2010, 01:03 PM   Nav to Top  #6
blanchedsoldier
Junior Trader
 
blanchedsoldier's Avatar
 
Join Date: Sep 2009
Location: Ireland
Posts: 24
Favorites: drys,bcs,pxwl
Rep Power: 121
Reputation: 35
blanchedsoldier is on a distinguished road
Thread Starter
Default NPHC starts possible reversal

NPHC is up 13% today. Time to make a decision.


Chronic Muscle & Joint Pain Relief Medication -Cobroxin
Nyloxin // Chronic Pain Relief



NPHC revenue is doubling each quarter.

NPHC revenue is up 4000% from last year

Half a million in Q4 09 and $850,000 in Q1 2010 with revenues expected to grow at least 50% - 100% each quarter.

One such wonder product is the 11th best selling pain reliver/ oil out of 328 other products on Amazon. This wonder drug is cobroxin and is partnered with XCHO for doemstic distribution and has had a massive rollout.

The sales have been unprecdented with sales forecast to be 8 - 10 times higher than first forecast in 2009. XCHO ( xena ) is also a hot stock with revenues increasing dramatically thanks to cobroxin.

NPHC at the Nasdaq conference underlined and stated the fact they would not dilute the share stock and have sufficent credit line.
Cobroxin is the 11th Bestseller on Amazon despite the fact it's only just been marketed in Q4 09 /Q1 2010.

The explosive new drug
New product Nyloxin has just found a new partner with one of the largest fortune 500 distributors in the world. Nutra Pharma Partners With Henry Schein for Distribution of Nyloxin-Branded Pain Relievers

PIPELINE
NPHC has an exciting pipeline with Phase III Drugs targeting large markets and also a half dozen at Phase II.

Technically

It has just hit the bottom after along bearish trend. It is possibly on the cusp of a trend reversal. Do your DD, love the company and study the chart and see what you think. It is up 15% today but still offers a huge upside of 300%.

Cobroxin:

Cobroxin is aimed at treating various levels of chronic pain. Using a pain scale of 1 to 10, Cobroxin may be used to treat pain in the range of 2-6. Moderate pain is defined as pain that interferes with sleep or work. Severe pain interferes with all activities (7-10) when a physician should be consulted.

Cobroxin™ for Chronic Pain - Clinical Studies
Chronic Muscle & Joint Pain Relief Medication -Cobroxin
Nyloxin // Chronic Pain Relief
blanchedsoldier is offline   Rate this post Yes | No Reply With Quote
Old 06-01-2010, 09:09 PM   Nav to Top  #7
blanchedsoldier
Junior Trader
 
blanchedsoldier's Avatar
 
Join Date: Sep 2009
Location: Ireland
Posts: 24
Favorites: drys,bcs,pxwl
Rep Power: 121
Reputation: 35
blanchedsoldier is on a distinguished road
Thread Starter
Default NPHC is a STRONG BUY

Look for any green tomorrow and that signals a BUY.
Volume average is usually 400,00 for the day. looking for a higher volume and a buy to sell ratio of at least 2:1 that would form a morningstar which you have to BUY into.

blanchedsoldier is offline   Rate this post Yes | No Reply With Quote
Old 06-03-2010, 12:59 AM   Nav to Top  #8
blanchedsoldier
Junior Trader
 
blanchedsoldier's Avatar
 
Join Date: Sep 2009
Location: Ireland
Posts: 24
Favorites: drys,bcs,pxwl
Rep Power: 121
Reputation: 35
blanchedsoldier is on a distinguished road
Thread Starter
Default Staying bullish with NPHC _reversal?

BUlls are winning the fight with the bears on this.

blanchedsoldier is offline   Rate this post Yes | No Reply With Quote
Old 06-03-2010, 10:45 AM   Nav to Top  #9
blanchedsoldier
Junior Trader
 
blanchedsoldier's Avatar
 
Join Date: Sep 2009
Location: Ireland
Posts: 24
Favorites: drys,bcs,pxwl
Rep Power: 121
Reputation: 35
blanchedsoldier is on a distinguished road
Thread Starter
Default

NPHC ..... Quietly making progress; a run is in the works.
blanchedsoldier is offline   Rate this post Yes | No Reply With Quote
Old 06-16-2010, 02:22 PM   Nav to Top  #10
Bullishonme
Junior Trader
 
Bullishonme's Avatar
 
Join Date: Jun 2010
Location: Florida
Posts: 9
Rep Power: 110
Reputation: 10
Bullishonme is on a distinguished road
Default

i admire your bravery on this one.

i have to say...it seems like a company which did one hell of a failed IPO at the exact wrong time. when the market crashed. not sure how to feel on this one, but if the fundamentals are any indicator...after almost 10 years of being traded...they still aren't profitable?

looks like they are either scraping or about to have some serious upside. need to dive into the business more.
Bullishonme is offline   Rate this post Yes | No Reply With Quote
Reply

Tags
agressive, biotech, bull, FDA, hot stock, NPHC, nutra

Similar Threads
Thread Thread Starter Forum Replies Last Post
Strong Buy: Breakout Profit Alert issued for Caleco Pharma Corp (CAEH) Major News! clayrubel US Penny Stock Picks 0 02-11-2010 01:45 PM
Strong Buy: CYNX: 3G/4G cell signal product: mkt over 2 billion tedw US Penny Stock Picks 4 12-21-2009 03:28 PM
Buy: New Pain Treatment Triumphs Morphine (OTC:NPHC) StocksHaven US Penny Stock Picks 0 09-11-2009 02:04 AM
Strong Buy: Online Presentation: Breakthrough Treatment Of Pain (OTC:NPHC) StocksHaven US Penny Stock Picks 0 09-02-2009 01:34 AM
Verizon - VZ play, new product in mid-May. MiFi better than WiFi IsDangerous Rumors & News 2 05-11-2009 09:15 AM


Thread Tools Search this Thread
Search this Thread:

Advanced Search

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is On